德方纳米(300769.SZ):定增申请获深交所审核通过
格隆汇2月17日丨德方纳米(300769.SZ)公布,公司于2022年2月16日收到深交所上市审核中心出具的《关于深圳市德方纳米科技股份有限公司申请向特定对象发行股票的审核中心意见吿知函》。
深交所发行上市审核机构对公司向特定对象发行股票的申请文件进行了审核,认为公司符合发行条件、上市条件和信息披露要求,具体审核意见以《审核中心意见落实函》为准。
后续深交所将按规定报中国证监会履行相关注册程序,同时要求公司收到《吿知函》后以临时公吿方式及时做好信息披露工作,并在十个工作日内汇总补充报送与审核问询回复相关的保荐工作底稿。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.